PRESENTATION

Q4 2023 — Presentation

Q4 2023PDF · 15 pages209 KB
Elevance Health
4Q 2023 Earnings Presentation
January 24, 2024

-- 1 of 15 --

2
Key Highlights
• 	Elevance Health delivered another solid year of financial and operational performance, reflecting the
balance and resilience of our diversified portfolio of businesses
• 	4Q 2023 adjusted diluted EPS of $5.62 grew 15.2% year-over-year
• 	2023 full year adjusted diluted EPS of $33.14 grew 16.2% year-over-year
• 	2018 – 2023 adjusted diluted EPS CAGR of 16% exceeded the high end of our long-term target growth rate
2023 Results
1
• 	2024 adjusted diluted EPS guidance of >$37.10 reflects growth of at least 12% year-over-year
• 	Benefit expense ratio projected to be 87.0% +/- 50 bps
• 	Operating gain projected to be greater than $10.3B, growth of >9% year-over-year
• 	Medical membership expected to end in the range of 45.8 – 46.6 million members
2024 Outlook
2
• 	Enhance the whole health of our members by serving as their lifetime, trusted health partner, especially
through maximizing continuity of coverage for those subject to Medicaid redeterminations and adding key
capabilities in Carelon in 2024. We will continue to live our purpose: to improve the health of humanity.
• 	Growth in 2024 will be driven by optimizing our Health Benefits business, including through the ongoing
margin recovery of our Commercial risk-based business, the strategic repositioning of our Medicare
Advantage plan offerings in certain markets, continued penetration of Carelon Services capabilities in our
health plans, and the transformation of our cost structure
• 	We will continue to invest in high-growth opportunities to build upon our foundation for sustained, long-
term growth
• 	We will scale Carelon’s existing capabilities and add new ones in 2024, driving incremental earnings and
accelerating our enterprise flywheel for growth
Strategic Priorities
3

-- 2 of 15 --

33
Key Highlights
• 	Elevance Health delivered another
solid year of financial and
operational performance
• 	Fourth quarter and full-year results
marked by solid top and bottom-line
growth
• 	Benefit expense ratio of 87.0% for the
full year represents an improvement
of 60 basis points from prior year
• 	Adjusted operating gain in 2023 grew
12.8% year-over-year to $9.4B
• 	Results reflect the balance and
resilience of our diversified portfolio
of businesses, our relentless focus on
customer experience and
affordability, and continued
investments in innovation
Fourth Quarter & Full Year 2023 Results
Change
(%/bps/$)
2022	2023
Change
(%/bps)
4Q 2022	4Q 2023	Elevance Health
9.3%	$155.7B	$170.2B	7.0%	$39.7B	$42.5B	Operating Revenue 1
(60) bps	87.6%	87.0%	(50) bps	89.7%	89.2%	Medical Loss Ratio
0 bps	11.3%	11.3%	20 bps	11.4%	11.6%
Adjusted Operating
Expense Ratio1,2
12.8%	$8.4B	$9.4B	3.3%	$1.3B	$1.4B
Adjusted Operating
Gain1,2
(30) bps	5.3%	5.0%	(20) bps	3.2%	3.0%	Operating Margin 1
22.9%	$1.5B	$1.8B	41.8%	$373M	$529M	Net Investment Income
16.2%	$28.53	$33.14	15.2%	$4.88	$5.62	Adjusted diluted EPS
($0.3B)	$8.4B	$8.1B	($1.5B)	($1.5B)	($3.0B)	Operating Cash Flow
1. 	See “Basis of Presentation” on page 11 herein.
2. 	See “GAAP Reconciliation” on pages 12 and 13 herein.

-- 3 of 15 --

44
2023 Actual	2024 Outlook	Elevance Health
$142.9B	Approximately Flat	Premium Revenue
$19.5B	Mid-Single Digit Growth	Product Revenue
$7.9B	Low Double-Digit Growth	Service Fees
$170.2B	Flat to Low-Single Digit Growth	Total Operating Revenue
87.0%	87.0% +/- 50 bps	Medical Loss Ratio
11.3%	11.1% +/- 50 bps	Adjusted Operating Expense Ratio
$9.4B	>$10.3B	Adjusted Operating Gain
$1.83B	$1.90B	Net Investment Income
$33.14	>$37.10	Adjusted Diluted EPS
$8.1B	>$8.1B	Operating Cash Flow
2024 Outlook
Key Highlights
• 	2024 full year guidance for adjusted
diluted earnings per share of greater
than $37.10 reflects growth of 12%
year-over-year and is consistent with
our long-term compound annual
growth rate target
• 	Health Benefits 2024 outlook reflects
continued optimization of our
commercial risk-based business,
improvement in Medicare earnings,
and a reset in Medicaid membership
associated with footprint changes
and ongoing redeterminations
• 	Carelon poised for strong growth in
2024 driven by new external client
wins and continued expansion of
services provided to Elevance Health
medical members

-- 4 of 15 --

55
Key Highlights
• 	Health Benefits delivered strong
fourth quarter and full year results as
we continued to optimize our business
while investing for growth and
responding to a dynamic environment
• 	Commercial Health Benefits business
successfully delivered margin
improvement and is on track to return
to pre-pandemic levels
• 	Government Health Benefits business
performed in line with expectations; we
continue to execute an extensive
renewal campaign to maximize
continuity of coverage for consumers
• 	2024 earnings growth will be driven by
continued optimization of the Health
Benefits business including Commercial
risk; strategic repositioning of Medicare
Advantage; and the transformation of
our cost structure
Change
(%/bps)
2022	2023
Change
(%/bps)
4Q 2022	4Q 2023	Health Benefits
7.3%	$138.5B	$148.6B	4.4%	$35.0B	$36.5B	Operating Revenue1
14.4%	$6.0B	$6.9B	(2.3%)	$785M	$767M	Operating Gain1
30 bps	4.3%	4.6%	(10) bps	2.2%	2.1%	Operating Margin 1
(1.2%)	47.5M	47.0M	Membership
1. 	See “Basis of Presentation” on page 11 herein.
2024 Outlook	Guidance
Approximately flat	Operating Revenue
25-50 basis points over 2023	Operating Margin
45.8M – 46.6M	Membership
Health Benefits
2023 Results | 2024 Outlook

-- 5 of 15 --

66
Key Highlights
• 	Carelon continues to advance its
strategy of integrating physical,
behavioral, social and pharmacy
services to deliver whole health,
affordably
• 	Carelon Services fourth quarter
operating revenue of $3.6 billion was
up 7% year-over-year and operating
gain of $102 million reflects an increase
of 162%, driven by improved
performance as we continue to scale
capabilities
• 	External pharmacy member growth
and the acquisition of the BioPlus
specialty pharmacy drove CarelonRx
fourth quarter operating revenue up
17% year-over-year, to $8.8 billion;
operating gain was $490 million, up 3%
• 	We continue to make significant
progress toward the near-term roll-out
of multiple new capabilities that will
enhance affordability and consumer
experiences for our customers
2023 Results | 2024 Outlook
Change
(%/bps)
2022	2023
Change
(%/bps)
4Q 2022	4Q 2023	Carelon
15.9%	$41.4B	$48.0B	14.1%	$10.9B	$12.4B	Operating Revenue 1
10.5%	$2.4B	$2.7B	15.2%	$514M	$592M	Operating Gain1
(30) bps	5.8%	5.5%	10 bps	4.7%	4.8%	Operating Margin 1
0.0%	308.3M	308.4M	(4.9%)	82.0M	78.0M	Adjusted Scripts
(1.6%)	105.0M	103.3M	Consumers Served
1. 	See “Basis of Presentation” on page 11 herein.
2024 Outlook	Guidance
High-Teens to Low-Twenties	Carelon Services Operating Revenue Growth
(30) – 0 basis points over 2023	Carelon Services Operating Margin
Low-Single Digit	CarelonRx Operating Revenue Growth
40 – 60 basis points over 2023	CarelonRx Operating Margin
Carelon

-- 6 of 15 --

77
Flywheel Supports Sustainable, Long-Term Growth
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Long-Term Adjusted Earnings Per Share
Compound Annual Growth Rate Target of 12 – 15%
Approximately 47M medical members
balanced across commercial,
Medicaid and Medicare, leveraging
the assets and capabilities of Carelon
to accelerate growth
Integrated portfolio of whole health
solutions connecting care across
physical, behavioral, social, and
pharmacy needs to bend the cost
curve, enhance consumer experiences,
and deliver whole health, affordably
Carelon

-- 7 of 15 --

88
Delivered on our Targets
1. 	Operating Revenue and Adjusted EPS Growth long-term guidance as of March 7, 2019. % of Benefit Expense managed by Carelon guidance as of March 23, 2023. 2023 Operating
Revenue and 2023 Adjusted EPS guidance as of January 25, 2023.
2. 	CAGR: Compound Annual Growth Rate.
Status	Actual	Initial Guidance1	Commitment
13% CAGR
(2018-2023)
10% – 12% CAGR 2	Operating Revenue Growth
16% CAGR
(2018-2023)
12% – 15% CAGR	Adjusted EPS Growth
21% in 2023	>20% in 2025	% of Benefit Expense Managed by Carelon
$170B	$164B	2023 Operating Revenue
$33.14	>$32.60	2023 Adjusted Diluted EPS

-- 8 of 15 --

99
Committed to Strong Growth Over the Long-Term
M&A/ Reinvest
in Core
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2022 	2027
Target
$156B
Upper Single
to Low Double
Digit CAGR2
2022 	2027
Target
Elevance Health
5.8%
Mid to Upper
Single Digit
2022 	2027
Target
$41B
Mid Teens
CAGR2
2022 	2027
Target
Carelon 3
4.3%
5.5% – 6.5%
2022 	2027
Target
$138B
Upper Single
Digit CAGR2
2022 	2027
Target
Health Benefits
Capital
Allocation
Long-Term Adjusted Earnings Per Share
Compound Annual Growth Rate Target of 12 – 15%
Operating
Margin 1
Revenue1
(in Billions)
1. 	2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials.
2. 	Five-Year Compound Annual Growth Rate target for 2022 – 2027.
3. 	The compound annual growth rate (CAGR) target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR
and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services.

-- 9 of 15 --

10
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our
views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial
projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services;
and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our
control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new
or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other
diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply
with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic
and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the
industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-
compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and
other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities
associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively
maintain and modernize our information systems; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical
malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks
associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support
goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to
repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential
negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further
increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in
particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated
with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

-- 10 of 15 --

11
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on the last page of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 11 of 15 --

12	12
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share
Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2022	2023	Change	2022	2023	(In millions, except per share data)
(0.6)%	$6,025	$5,987	(9.8)%	$949	$856	Shareholders' net income - As reported
(131)	—	(84)	—	Impact of Accounting Standards Update 2018-12 Adoption
1.6%	$5,894	$5,987	(1.0)%	$865	$856	Shareholders' net income - Restated
Add / (Subtract):
550	694	111	336	Net losses on financial instruments
767	885	247	217	Amortization of other intangible assets
72	213	36	59	Transaction and integration related costs
39	719	39	22	Business optimization charges
12	6	1	1	Litigation expenses
(44)	(8)	(20)	(8)	BCBSA litigation settlement
(363)	(628)	(102)	(158)	Tax impact of non-GAAP adjustments
1,033	1,881	312	469	Net adjustment items
13.6%	$6,927	$7,868	12.6%	$1,177	$1,325	Adjusted shareholders' net income
1.7%	$24.81	$25.22	(7.6)%	$3.93	$3.63	Shareholders’ earnings per diluted share - As reported
(0.53)	—	(0.34)	—	Impact of Accounting Standards Update 2018-12 Adoption
3.9%	$24.28	$25.22	1.1%	$3.59	$3.63	Shareholders’ earnings per diluted share - Restated
Add / (Subtract):
2.27	2.92	0.46	1.42	Net losses on financial instruments
3.16	3.73	1.02	0.92	Amortization of other intangible assets
0.30	0.90	0.15	0.25	Transaction and integration related costs
0.16	3.03	0.16	0.09	Business optimization charges
0.05	0.03	—	—	Litigation expenses
(0.18)	(0.03)	(0.08)	(0.03)	BCBSA litigation settlement
(1.50)	(2.65)	(0.42)	(0.67)	Tax impact of non-GAAP adjustments
4.25	7.92	1.29	1.99	Net adjustment items
16.2%	$28.53	$33.14	15.2%	$4.88	$5.62	Adjusted shareholders’ earnings per diluted share

-- 12 of 15 --

13	13
Elevance Health GAAP Reconciliation — Operating Expense Ratio and
Operating Gain
Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2022	2023	Change	2022	2023	(In millions)
13.6%	$17,686	$20,087	9.6%	$4,562	$4,999	Operating expense - As reported
14	—	5	—	Impact of Accounting Standards Update 2018-12 Adoption
13.5%	$17,700	$20,087	9.5%	$4,567	$4,999	Operating expense - Restated
Add / (Subtract):
(72)	(213)	(36)	(59)	Transaction and integration related costs
(39)	(719)	(39)	(22)	Business optimization charges
(12)	(6)	(1)	(1)	Litigation expenses
44	8	20	8	BCBSA litigation settlement
(79)	(930)	(56)	(74)	Net adjustment items
8.7%	$17,621	$19,157	9.2%	$4,511	$4,925	Adjusted operating expense
1.5%	$7,600	$7,715	(4.2)%	$1,045	$1,001	Income before income tax expense
(1,485)	(1,825)	(373)	(529)	Net investment income
550	694	111	336	Net losses on financial instruments
851	1,030	229	259	Interest expense
767	885	247	217	Amortization of other intangible assets
2.6%	$8,283	$8,499	2.0%	$1,259	$1,284	Reportable segments operating gain
79	930	56	74	Adjustment items
12.8%	$8,362	$9,429	3.3%	$1,315	$1,358	Reportable segments adjusted operating gain
9.3%	$155,660	$170,209	7.0%	$39,667	$42,454	Operating revenue
40 bp	11.4%	11.8%	30 bp	11.5%	11.8%	Operating expense ratio
— bp	11.3%	11.3%	20 bp	11.4%	11.6%	Adjusted operating expense ratio

-- 13 of 15 --

14	14
Elevance Health GAAP Reconciliation — 2024 Outlook
Full Year 2024
Outlook
Greater than $34.29	Shareholders’ earnings per diluted share
Add / (Subtract):
$1.93	Amortization of other intangibles
$1.35	Net losses on financial instruments
$0.31	Transaction and integration related costs
$0.03	Litigation expenses
Approximately $(0.81)	Tax impact of non-GAAP adjustments
$2.81	Net adjustment items
Greater than $37.10	Adjusted shareholders’ earnings per diluted share

-- 14 of 15 --



-- 15 of 15 --